A modified form of beta-glucerebrosidase that catalyses the hydrolysis of glucocerebroside in reticuloendothelial system lysosomes, which is the most effective therapy for type-1 Gaucher disease, resulting in decreased hepatospenomegaly, haematologic defects, increased bone mineralisation and reversal of cachexia seen in these patients.


 A recombinant glucocerebrosidase used for Gaucher's disease
References in periodicals archive ?
Specific therapy for the nonneuronopathic manifestations of Gaucher disease has been available since 1991 firstly in the form of the macrophage targeted placenta-derived glucocerebrosidase (alglucerase, Ceredase [R], Genzyme Corporation, MA) (7), and subsequently (1994 in USA and 1997 in Europe) by recombinant human enzyme, imiglucerase (Cerezyme[R], Genzyme Corporation, MA) (8).
Since introducing Ceredase in 1991, Genzyme has engaged in extensive basic science research to further improve the management of Gaucher patients.
Aliski worked at Genzyme Corporation, a biopharmaceutical company focused on serious diseases, including genetic disorders, where he served as Vice President of Health Systems and Vice President of Patient and Product Services, responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products, including Cerezyme and Ceredase.
When Congress called Genzyme to task for profiteering, the company's CEO, Henri Termeer, fired back in the pages of The Wall Street Journal that the company had every right to charge what the market would bear, because it had risked everything to develop Ceredase.
The only medicine currently available to treat it, called Ceredase, costs an average of $160,000 a year, said Cramer.
The nonrecombinant products ceredase and adenosine deaminase (PEG-ADA) illustrate the potential impact of chronic lifetime administration of drugs.
Aliski also brings a wealth of relevant commercial experience from his eight years at Genzyme Corporation where he was primarily responsible for reimbursement, distribution and patient support services for the Ceredase and Cerezyme, the first enzyme replacement therapy to treat Gaucher Disease.
Cerezyme (imiglucerase for injection) and its predecessor Ceredase (alglucerase injection) have been marketed in the United States since 1991, and Ceredase was first approved in Europe in 1994.
Cerezyme (imiglucerase for injection) and its predecessor Ceredase (alglucerase injection), have been marketed in the United States since 1991.
Operating profit margins in the quarter were impacted by a change in the overall business mix, which included a higher percentage of revenue generated from Ceredase and Synagis programs.
Genzyme launched its first tissue-derived enzyme replacement product, Ceredase, in April 1991, to treat Gaucher disease, after conducting a single clinical trial.
International growth of Cerezyme and Ceredase was strong, despite the effect of the strong dollar on European sales.